A Study of Efficacy and Safety of Depemokimab Compared With Placebo in Adults and Adolescents With at Risk Type 2 Asthma
NCT07456033
This study is recruiting at 16 US sites in 10 states, according to its ClinicalTrials.gov record last updated .
Summary
The aim of this study is to evaluate the efficacy of depemokimab administered as an adjunctive therapy, in participants with Type 2 asthma at risk of exacerbations compared to the guideline recommended standard of care (SoC).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Asthma
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 12 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- GlaxoSmithKline
- Last updated on ClinicalTrials.gov
- August 17, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arkansas · 1
- GSK Investigational Site · Little Rock, AR
California · 1
- GSK Investigational Site · Newport Beach, CA
Colorado · 1
- GSK Investigational Site · Aurora, CO
Florida · 6
- GSK Investigational Site · Aventura, FL
- GSK Investigational Site · Kissimmee, FL
- GSK Investigational Site · Lake Worth, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
- GSK Investigational Site · Miami, FL
Louisiana · 1
- GSK Investigational Site · Shreveport, LA
Oklahoma · 1
- GSK Investigational Site · Oklahoma City, OK
Pennsylvania · 2
- GSK Investigational Site · DuBois, PA
- GSK Investigational Site · Wyomissing, PA
South Dakota · 1
- GSK Investigational Site · Rapid City, SD
Texas · 1
- GSK Investigational Site · San Antonio, TX
Virginia · 1
- GSK Investigational Site · Burke, VA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.